Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis

Marques, Cindy; Lefevre, Leïla Bengrine; Barmo, Serge; Lorenzo, Camille; Leclercq, M.; Leroux, Gaëlle; Comarmond, C.; Chapelon-Abric, C.; Domont, Fanny; Vautier, Mathieu; Saadoun, David; Cacoub, P.

doi:10.55563/clinexprheumatol/b7zd6b

Cited by 9 publications

(6 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The rate of our sarcoidosis patients suffering from COVID‐19 pneumonia after infection with SARS‐CoV‐2 was significantly lower than that of other pre‐existing ILDs but higher than that of the sarcoidosis cohort in France and America. In our study, 17 patients (9%) suffered from COVID‐19 pneumonia after infection with SARS‐CoV‐2, while 4% of sarcoidosis patients suffered from COVID‐19 pneumonia in France (which was similar to the patients with other inflammatory and autoimmune disorders in France) 37 . In Cincinnati's worldwide sarcoidosis patients' reported outcome study, the incidence of COVID‐19 pneumonia was 2.23% 38 .…”

Section: Discussionsupporting

confidence: 49%

See 1 more Smart Citation

Risk factors associated with COVID‐19 pneumonia in Chinese patients with pre‐existing interstitial lung disease during the SARS‐CoV‐2 pandemic

Shao,

Shi,

Chen

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

In China, the emergence of a nationally widespread epidemic infection of severe acute respiratory syndrome coronavirus 2 (SARS‐COV‐2) has appeared within a month since December 7, 2022. To evaluate the risk factors for suffering from coronavirus disease 2019 (COVID‐19) pneumonia due to infection with SARS‐CoV‐2 in different kinds of interstitial lung disease (ILD) patients with diverse immunizations, we conducted this retrospective study on 525 patients with ILDs who underwent regular follow‐up in our ILD clinic. Among them, 128 ILD patients (24.4%) suffered from COVID‐19 pneumonia after SARS‐CoV‐2 infection. Patients were older with a male predominance in the pneumonia group than in the nonpneumonia group (65.0 ± 10.0 years vs. 56.4 ± 11.7 years, p < 0.001, 55.5% vs. 39.5%, p = 0.002, respectively). Connective tissue disease‐associated ILD (CTD‐ILD) (25%), idiopathic pulmonary fibrosis (23.4%), and interstitial pneumonia with autoimmune features (21.1%) were the main pre‐existing ILDs in the pneumonia group. In Cox multivariable analysis, only male sex and corticosteroid use were risk factors for COVID‐19 pneumonia after infection. Two or three doses of vaccination were a protective factor for pre‐existing ILD patients suffering from COVID‐19 pneumonia. More than two doses of vaccination were strongly recommended for pre‐existing ILD patients, particularly for males who were administered corticosteroids.

show abstract

Section: Discussionsupporting

confidence: 49%

“…In France's cohort, the incidence of hospitalization and death were 37.5% and 12.5%, respectively (which was higher than that in the general population in France). It might be associated with systemic corticosteroids and comorbidities, especially diabetes 37 . In Cincinnati's cohort, the hospitalization rate was 15.8%.…”

Section: Discussionmentioning

confidence: 97%

Risk factors associated with COVID‐19 pneumonia in Chinese patients with pre‐existing interstitial lung disease during the SARS‐CoV‐2 pandemic

Shao,

Shi,

Chen

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…4 A study from France indicates that the hospitalization and mortality rates were higher in sarcoidosis patients with COVID -19 than in the general population. 41 In our study, only 53 deaths were reported in the analyzed period (0.34% of all cases), but approximately half of them occurred in the almost 2 -year observation period after the COVID -19 outbreak in Poland. There were significant differences in age and fatal hospitalization rates among patients with sarcoidosis and COVID -19, as compared with those without COVID -19.…”

Section: Conflict Of Interest None Declaredmentioning

confidence: 52%

Hospitalizations of sarcoidosis patients before and during the COVID-19 pandemic in Poland

Bogdan,

Kanecki,

Tyszko

et al. 2024

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

Hospitalizations of sarcoidosis patients before and during the COVID -19 pandemic 1 was estimated at 35.22 per 100 000 population in a 7 -year period. 3 Another American study indicated an annual disease incidence of 10 per 100 000 population. 4 In Canada, in the years 1996-2014, the incidence of sarcoidosis fell from 7.9 to 6.8 per 100 000 population. In 2015, the disease prevalence was 143 per 100 000. 5 The incidence rates vary significantly between different ethnicities; for example, in South Korea, they reach approximately 0.85 per 100 000, 6 whereas in black INTROduCTION Sarcoidosis is a multisystemic granulomatous disease, mostly affecting the lungs and lymphatic system. According to epidemiologic studies, there are significant variations in the disease frequency across countries, depending on age, sex, geographic region, and ethnicity. 1,2 A study from the United States 3 identified 37 688 individuals with sarcoidosis at a mean age of 50.5 years, 59.3% of whom were women. The prevalence of sarcoidosis in the United States

show abstract

“…[17]. Описанный нами летальный исход также созвучен данным французских исследователей, отметивших, что тяжесть COVID-19 у пациентов с саркоидозом была связана с сопутствующими заболеваниями и лечением саркоидоза системными кортикостероидами [18]. В Испании было установлено, что COVID-19 был одним из независимых предикторов смерти у мужчин и женщин, госпитализированных с тяжелым саркоидозом [19].…”

Section: Covid-19unclassified

Characteristics of patients with sarcoidosis who referred to a pulmonologist during the COVID-19 pandemic

Vizel,

Shakirova

et al. 2023

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. During the COVID-19 pandemic, the first experience was gained in managing patients with sarcoidosis in the face of a dangerous viral infection, a combination of two diseases and vaccination against COVID-19. Publications on this issue remain ambiguous, which made it relevant to assess the management of patients with sarcoidosis during a pandemic and the features of vaccination of these patients.Aim. To assess the condition of patients with sarcoidosis who turned to a pulmonologist during the pandemic, to compare the parameters of patients with sarcoidosis who had and did not have COVID-19, with mild and severe course, as well as to evaluate the effectiveness and safety of vaccination.Materials and methods. The study was a retrospective, observational, non-interventional study. We included 299 patients who visited a pulmonologist in 176 (58.9%) of whom developed COVID-19 and 123 (41.1%) did not have a viral disease. Information on survivors of COVID-19 was collected using the COVIZ application. Data summarization and statistical processing were carried out using the SPPS-18 program (IBM) p < 0.05 values were considered statistically significant.Research results. Comparison of data of patients with sarcoidosis who fell ill and did not become ill with COVID-19 during the pandemic period showed that those who fell ill with this viral infection were significantly younger, more often had extrapulmonary manifestations of sarcoidosis. Patients did not differ in the radiation stage of sarcoidosis, the frequency of Löfgren’s syndrome, and the frequency of familial cases of granulomatosis. The use of methotrexate was accompanied by a higher incidence of COVID-19, the probability of getting sick was more than 3 times higher (OR = 3.39; 95% CI 1.12–10.28). Among those who received GCS (n = 49), those who received a dose of 10 mg prednisolone equivalent and above (OR = 12.056; CI95% 2.12–68.5) were more likely to develop COVID-19. The risk of developing COVID-19 in those who were not vaccinated was significantly higher than in those who received the vaccine after a viral illness (OR = 2.50; CI95% 1.75–3.58). One case of death is presented.Conclusion. A retrospective analysis of cases of sarcoidosis during the COVID-19 pandemic indicated a favorable course of both diseases when combined. Negative prognostic factors were the use of immunosuppressive therapy for sarcoidosis and severe comorbidities of the cardiovascular system. Vaccination against COVID-19 was effective and safe in patients with pulmonary sarcoidosis.

show abstract

Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis

Cited by 9 publications

References 2 publications

Risk factors associated with COVID‐19 pneumonia in Chinese patients with pre‐existing interstitial lung disease during the SARS‐CoV‐2 pandemic

Risk factors associated with COVID‐19 pneumonia in Chinese patients with pre‐existing interstitial lung disease during the SARS‐CoV‐2 pandemic

Hospitalizations of sarcoidosis patients before and during the COVID-19 pandemic in Poland

Characteristics of patients with sarcoidosis who referred to a pulmonologist during the COVID-19 pandemic

Contact Info

Product

Resources

About